Aerosol drug delivery to the lungs during nasal high flow therapy: An in vitro study
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Aerosol drug delivery to the lungs during nasal high flow therapy : An in vitro study. / Wallin, Martin; Tang, Patricia; Chang, Rachel Yoon Kyung; Yang, Mingshi; Finlay, Warren H.; Chan, Hak Kim.
In: BMC Pulmonary Medicine, Vol. 19, No. 1, 42, 15.02.2019.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Aerosol drug delivery to the lungs during nasal high flow therapy
T2 - An in vitro study
AU - Wallin, Martin
AU - Tang, Patricia
AU - Chang, Rachel Yoon Kyung
AU - Yang, Mingshi
AU - Finlay, Warren H.
AU - Chan, Hak Kim
PY - 2019/2/15
Y1 - 2019/2/15
N2 - Background: Aerosol delivery through a nasal high flow (NHF) system is attractive for clinicians as it allows for simultaneous administration of oxygen and inhalable drugs. However, delivering a fine particle fraction (FPF, particle wt. fraction < 5.0 μm) of drugs into the lungs has been very challenging, with highest value of only 8%. Here, we aim to develop an efficient nose-to-lung delivery system capable of delivering improved quantities (FPF > 16%) of dry powder aerosols to the lungs via an NHF system. Methods: We evaluated the FPF of spray-dried mannitol with leucine with a next generation impactor connected to a nasopharyngeal outlet of an adult nasal airway replica. In addition, we investigated the influence of different dispersion (20-30 L/min) and inspiratory (20-40 L/min) flow rates, on FPF. Results: We found an FPF of 32% with dispersion flow rate at 25 L/min and inspiratory flow rate at 40 L/min. The lowest FPF (21%) obtained was at the dispersion flow rate at 30 L/min and inspiratory flow rate at 30 L/min. A higher inspiratory flow rate was generally associated with a higher FPF. The nasal cannula accounted for most loss of aerosols. Conclusions: In conclusion, delivering a third of inhalable powder to the lungs is possible in vitro through an NHF system using a low dispersion airflow and a highly dispersible powder. Our results may lay the foundation for clinical evaluation of powder aerosol delivery to the lungs during NHF therapy in humans.
AB - Background: Aerosol delivery through a nasal high flow (NHF) system is attractive for clinicians as it allows for simultaneous administration of oxygen and inhalable drugs. However, delivering a fine particle fraction (FPF, particle wt. fraction < 5.0 μm) of drugs into the lungs has been very challenging, with highest value of only 8%. Here, we aim to develop an efficient nose-to-lung delivery system capable of delivering improved quantities (FPF > 16%) of dry powder aerosols to the lungs via an NHF system. Methods: We evaluated the FPF of spray-dried mannitol with leucine with a next generation impactor connected to a nasopharyngeal outlet of an adult nasal airway replica. In addition, we investigated the influence of different dispersion (20-30 L/min) and inspiratory (20-40 L/min) flow rates, on FPF. Results: We found an FPF of 32% with dispersion flow rate at 25 L/min and inspiratory flow rate at 40 L/min. The lowest FPF (21%) obtained was at the dispersion flow rate at 30 L/min and inspiratory flow rate at 30 L/min. A higher inspiratory flow rate was generally associated with a higher FPF. The nasal cannula accounted for most loss of aerosols. Conclusions: In conclusion, delivering a third of inhalable powder to the lungs is possible in vitro through an NHF system using a low dispersion airflow and a highly dispersible powder. Our results may lay the foundation for clinical evaluation of powder aerosol delivery to the lungs during NHF therapy in humans.
KW - Aerosol
KW - Inhalable drugs
KW - Lungs
KW - Nasal cannula
KW - Nasal high flow
KW - Powders
KW - Pulmonary disease, chronic obstructive
U2 - 10.1186/s12890-019-0807-9
DO - 10.1186/s12890-019-0807-9
M3 - Journal article
C2 - 30767769
AN - SCOPUS:85061581347
VL - 19
JO - B M C Pulmonary Medicine
JF - B M C Pulmonary Medicine
SN - 1471-2466
IS - 1
M1 - 42
ER -
ID: 221825339